Journal Article

Medical options to fight mortality in end-stage renal disease: a review of the literature

Rafael Kramann, Jürgen Floege, Markus Ketteler, Nikolaus Marx and Vincent M. Brandenburg

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 27, issue 12, pages 4298-4307
Published in print December 2012 | ISSN: 0931-0509
Published online October 2012 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/gfs400
Medical options to fight mortality in end-stage renal disease: a review of the literature

Show Summary Details

Preview

Many therapeutic strategies for end-stage renal disease (ESRD) patients have failed to exhibit survival improvement in large-scale randomized controlled trials (RCTs). The current review gives an overview on the medical strategies for treatment of ESRD patients that have previously been tested in RCTs with mortality reduction as pre-specified study endpoint. We identified 19 RCTs with the following therapeutic strategies: haematocrit increase by erythropoietin (n = 1), growth hormone application (n = 1), lipid-lowering by statins (n = 3), renin–angiotensin system blockage (n = 4), β-receptor blockage (n = 1), homocysteine lowering (n = 5), application of anti-oxidative substances (n = 2), omega-3-fatty-acid supplementation (n = 1) and calcium-free phosphate binders (n = 1). While several of these studies were able to demonstrate reductions in hard cardiovascular endpoints such as myocardial infarction, survival improvement in ESRD patients was demonstrated in only three studies. The substances tested in these three trials were telmisartan, candesartan and carvedilol. In summary, most pharmaceutical mono-interventions failed to reduce mortality in ESRD patients, i.e. a multi-morbid population. Apart from the issues relating to future trial design, this raises the question of whether we need multi-faceted interventions to improve this dismal situation. Until then, nephrologists are left with little evidence and lots of opinions.

Keywords: end-stage renal disease; cardiovascular mortality; treatment; mortality; cardiorenal syndrome

Journal Article.  5706 words.  Illustrated.

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.